Common pain point
Maintaining compliance when it comes to 340B Orphan Drug Exclusion requirements is a challenge that not every system can meet — and negotiating discounts on orphan drugs can often go overlooked.
Our Orphan Drug Opportunity service helps you verify that you have the most up-to-date list of orphan drugs on hand and that they are excluded from 340B. We will also help you evaluate and negotiate existing contracts with pharma manufacturers to optimize orphan drug prices.
Interested in knowing more? Complete the form below to request a free needs assessment and see how together we can optimize your orphan drug compliance and pricing.